Amylyx Pharmaceuticals, Inc.

AMLX

Amylyx Pharmaceuticals, Inc.

AMLX

Insider Sentiment (TTM):

Last Purchase:2026-05-21Last Sale:2026-03-02Shares Purchased (TTM):11,900Shares Sold (TTM):241,840

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:113,531,472Shares Outstanding:110,563,360Institutional Ownership Pct.:102.68%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	49	229	227	225	58	60	77	72	75	171	170	135
Short Term Investments	-	-	-	-	-	-	-	-	235	203	201	220
Marketable Securities Current	201	51	90	119	123	144	99	163	-	-	201	-
Accounts Receivable Net Current	-	-	0	0	0	0	0	2	4	20	40	29
Inventory Net	-	-	-	-	-	-	-	-	-	-	38	32
Prepaid Expense And Other Assets Current	6	5	7	9	6	12	12	9	13	17	15	17
Assets Current	256	285	324	353	187	216	189	245	327	411	465	434
Property Plant And Equipment Net	0	0	0	0	0	1	1	1	1	2	3	3
Restricted Cash Equivalents Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	5	5	5	5	6	1	2	5	3	3	4	4
Inventory Noncurrent	-	-	-	-	-	-	-	-	-	-	45	24
Other Assets Noncurrent	-	3	-	3	-	0	0	0	0	0	1	0
Assets	265	294	333	363	195	220	194	251	332	417	517	467
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	6	4	4	5	3	5	3	1	5	21	22	6
Accrued Liabilities Current	15	11	18	19	17	12	24	50	63	68	58	37
Operating Lease Liability Current	1	1	1	1	1	1	2	2	2	2	2	2
Liabilities Current	21	16	23	26	21	18	28	54	70	92	82	46
Operating Lease Liability Noncurrent	4	4	5	5	5	0	0	1	1	1	2	3
Liabilities	25	20	27	31	27	18	29	55	71	93	84	48
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,075	1,066	1,056	1,050	851	844	772	765	758	748	738	728
Retained Earnings Accumulated Deficit	-836	-793	-751	-718	-684	-643	-607	-569	-496	-424	-305	-310
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	1	1	0	-0	1	-0	-0	0	-0
Stockholders Equity	239	273	305	332	168	201	165	196	261	324	433	418
Liabilities And Stockholders Equity	265	294	333	363	195	220	194	251	332	417	517	467
Preferred Stock Par Or Stated Value Per Share	0	0	-	0	0	0	-	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	-	10	10	10	-	10	10	10	10	10
Preferred Stock Shares Issued	0	0	-	-	-	-	-	-	-	-	-	0
Preferred Stock Shares Outstanding	0	0	-	-	-	-	-	-	-	-	-	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	111	111	110	110	89	89	69	69	68	68	68	68
Shares Outstanding	111	111	110	110	89	89	69	69	68	68	68	68

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.59%	17.04%	21.12%	-	-	-	-	-	-	-	-	-
2025	12.45%	38.21%	77.95%	19.64%	85.20%	80.74%	20.22%	-1.04%	26.48%	-3.97%	20.77%	-3.76%
2024	-8.99%	0.53%	4.23%	23.33%	71.11%	195.00%	-15.29%	-40.83%	-44.95%	21.59%	78.07%	76.41%
2023	-	-	-	3.07%	-13.51%	-25.65%	15.99%	20.07%	25.45%	-82.52%	-88.67%	-90.53%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	12.12	17.85	14.27	13.70	8.72	12.05	6.67	4.55	4.66	4.48	5.66	9.52
Quick Ratio	11.86	17.52	13.98	13.34	8.45	11.40	6.23	4.38	4.48	4.30	5.01	8.43
Working Capital	235.19M	269.06M	300.98M	327.59M	165.47M	198.21M	161.03M	191.35M	256.64M	318.90M	382.62M	388.49M
Leverage & Debt
Debt to Equity	0.11	0.07	0.09	0.09	0.16	0.09	0.18	0.28	0.27	0.29	0.19	0.12
Debt Ratio	0.10	0.07	0.08	0.08	0.14	0.08	0.15	0.22	0.21	0.22	0.16	0.10
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	-0.00	-0.00	-0.00	0.25	0.55	0.76	0.96	0.84	0.91
Days Sales Outstanding TTM	-	-	-	-511.27	-3,073.92	-2,962.90	84.59	28.87	22.95	17.38	26.53	18.29
Receivables Turnover TTM	-	-	0.00	-0.71	-0.12	-0.12	4.31	12.64	15.91	21.00	13.76	19.95
Per Share Metrics
Diluted EPS TTM	-1.37	-1.36	-1.53	-1.60	-2.10	-2.55	-4.43	-3.81	-2.44	-1.05	0.70	0.03
Free Cash Flow Per Share TTM	-1.17	-1.09	-1.31	-1.23	-1.41	-2.42	-2.46	-1.40	-0.88	0.23	0.16	-0.78
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	89.49%	90.71%	90.47%	93.58%
Operating Profit Margin TTM	-	-	-	23,660.30%	79,106.43%	18,113.52%	-360.22%	-138.51%	-59.50%	-20.42%	10.19%	-2.63%
Net Profit Margin TTM	-	-	-	22,448.42%	75,341.37%	17,205.74%	-345.36%	-132.05%	-55.52%	-17.86%	12.94%	0.62%
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-100.00%	-100.34%	-100.08%	-100.32%	-77.06%	-33.22%	55.71%	324.95%	1,612.94%	-
Net Income Growth (1Y)	-18.93%	-31.41%	-52.03%	-42.47%	13.10%	207.84%	-712.42%	-14,232.14%	127.80%	-52.27%	-124.84%	-
EPS Growth (1Y)	-35.01%	-46.84%	-65.44%	-58.03%	-13.69%	143.74%	-704.26%	-14,091.67%	125.15%	-53.07%	-121.61%	-
Valuation Metrics
P/E TTM	-13.13	-10.24	-7.89	-8.50	-3.05	-1.39	-0.85	-0.85	-0.78	-2.71	20.09	672.31
P/B TTM	8.35	5.63	3.74	3.82	3.40	1.51	1.56	1.12	0.49	0.59	2.28	2.95
P/S TTM	-	-	-	-1,907.36	-2,294.69	-238.50	2.95	1.12	0.43	0.48	2.60	4.20
Market Cap	2.00B	1.54B	1.14B	1.27B	571.38M	303.37M	257.58M	220.62M	129.25M	192.71M	989.69M	1.23B
Enterprise Value	1.95B	1.31B	915.70M	1.04B	513.29M	242.15M	180.19M	147.34M	53.53M	22.15M	819.49M	1.10B
Calculated Values
Free Cash Flow TTM	-129.63M	-120.53M	-123.48M	-114.70M	-125.89M	-207.12M	-167.84M	-95.62M	-59.56M	15.44M	10.68M	-52.83M
Net Debt	-49.33M	-230.12M	-226.65M	-226.16M	-58.09M	-61.21M	-77.39M	-73.28M	-75.72M	-170.55M	-170.20M	-135.26M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-21Purchase

Owner: Firestone, Karen

Title: -

Shares: 3,800

Price/Share: $13.51

Value: $51,338.00

Shares Owned: 66,900

Relationship: Director

Ownership: Direct

2026-03-02Sale

Owner: Klee, Justin B.

Title: Co-Chief Executive Officer

Shares: 29,282

Price/Share: $14.47

Value: $423,710.54

Shares Owned: 3,334,616

Relationship: Director,Officer

Ownership: Direct

2026-03-02Sale

Owner: Bedrosian, Camille L

Title: Chief Medical Officer

Shares: 6,461

Price/Share: $14.58

Value: $94,201.38

Shares Owned: 169,295

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Frates, James M

Title: Chief Financial Officer

Shares: 7,909

Price/Share: $14.52

Value: $114,838.68

Shares Owned: 165,638

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Mazzariello, Gina

Title: Chief Legal Officer

Shares: 6,844

Price/Share: $14.52

Value: $99,374.88

Shares Owned: 134,430

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-21	Firestone, Karen	Director	-	Direct	Purchase	3,800	13.51	$51,338.00	66,900	4
2026-03-02	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	29,282	14.47	$423,710.54	3,334,616	4
2026-03-02	Bedrosian, Camille L	Officer	Chief Medical Officer	Direct	Sale	6,461	14.58	$94,201.38	169,295	4
2026-03-02	Frates, James M	Officer	Chief Financial Officer	Direct	Sale	7,909	14.52	$114,838.68	165,638	4
2026-03-02	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	6,844	14.52	$99,374.88	134,430	4
2026-03-02	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	29,282	14.48	$424,003.36	3,334,683	4
2026-02-23	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	3,419	14.14	$48,344.66	141,274	4
2026-02-02	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	3,448	14.65	$50,513.20	144,693	4
2026-02-02	Frates, James M	Officer	Chief Financial Officer	Direct	Sale	3,557	14.65	$52,110.05	173,547	4
2026-02-02	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	15,500	14.69	$227,695.00	3,363,898	4
2026-02-02	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	15,500	14.68	$227,540.00	3,363,965	4
2026-01-16	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	1,974	13.83	$27,300.42	3,379,465	4
2026-01-16	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	1,995	13.89	$27,710.55	3,379,398	4
2026-01-06	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	7,715	11.09	$85,559.35	3,317,586	4
2026-01-06	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	7,715	11.09	$85,559.35	3,317,632	4
2026-01-06	Frates, James M	Officer	Chief Financial Officer	Direct	Sale	3,326	11.11	$36,951.86	177,104	4
2025-12-23	Firestone, Karen	Director	-	Direct	Purchase	8,100	12.45	$100,845.00	63,100	4
2025-12-01	Bedrosian, Camille L	Officer	Chief Medical Officer	Direct	Sale	6,580	14.35	$94,423.00	175,756	4
2025-09-30	Bedrosian, Camille L	Officer	Chief Medical Officer	Direct	Sale	12,039	14.58	$175,528.62	182,336	4
2025-09-30	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	8,828	14.58	$128,712.24	148,141	4
2025-09-30	Frates, James M	Officer	Chief Financial Officer	Direct	Sale	10,558	14.65	$154,674.70	280,430	4
2025-09-30	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	29,975	14.69	$440,332.75	3,325,301	4
2025-09-30	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	29,933	14.67	$439,117.11	3,325,347	4
2025-08-13	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	15,000	8.34	$125,100.00	156,969	4
2025-03-31	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	21,490	3.47	$74,570.30	3,355,280	4
2025-03-31	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	21,490	3.46	$74,355.40	3,355,276	4
2025-03-31	Bedrosian, Camille L	Officer	Chief Medical Officer	Direct	Sale	12,425	3.47	$43,114.75	194,375	4
2025-03-31	Frates, James M	Officer	Chief Financial Officer	Direct	Sale	10,896	3.47	$37,809.12	290,988	4
2025-03-31	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	9,192	3.48	$31,988.16	187,969	4
2025-03-20	Zeiher, Bernhardt G	Director	-	Direct	Purchase	10,000	3.70	$37,000.00	10,000	4
2025-03-03	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	1,611	3.12	$5,026.32	133,310	4
2025-03-03	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	4,595	3.17	$14,566.15	3,196,652	4
2025-03-03	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	4,595	3.15	$14,474.25	3,196,648	4
2025-02-24	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	4,169	3.15	$13,132.35	134,921	4
2025-02-03	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	11,851	3.47	$41,122.97	3,201,247	4
2025-02-03	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	3,678	3.49	$12,836.22	139,090	4
2025-02-03	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	11,855	3.47	$41,136.85	3,164,933	4
2025-01-06	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	7,471	4.04	$30,182.84	3,176,788	4
2025-01-06	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	7,471	4.05	$30,257.55	3,213,098	4
2024-12-02	Bedrosian, Camille L	Officer	Chief Medical Officer	Direct	Sale	5,421	5.54	$30,032.34	138,380	4
2024-09-30	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	18,589	3.20	$59,484.80	3,220,569	4
2024-09-30	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	18,589	3.20	$59,484.80	3,120,569	4
2024-09-30	Bedrosian, Camille L	Officer	Chief Medical Officer	Direct	Sale	11,442	3.20	$36,614.40	143,801	4
2024-09-30	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	8,709	3.20	$27,868.80	142,768	4
2024-09-12	Frates, James M	Officer	Chief Financial Officer	Direct	Purchase	40,000	2.53	$101,200.00	233,464	4
2024-09-05	Firestone, Karen	Director	-	Direct	Purchase	50,000	2.13	$106,500.00	55,000	4
2024-09-03	Milne, George M Jr	Director	-	Direct	Purchase	100,000	2.20	$220,000.00	858,571	4
2024-05-15	Quimi, Daphne	Director	-	Direct	Purchase	2,250	1.89	$4,252.50	5,000	4
2024-05-15	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	10,455	1.88	$19,655.40	151,477	4
2024-03-05	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	4,135	18.73	$77,448.55	3,023,002	4
2024-03-05	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	1,540	18.73	$28,844.20	81,372	4
2024-03-05	Frates, James M	Officer	Chief Financial Officer	Direct	Sale	1,792	18.73	$33,564.16	134,784	4
2024-03-05	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	4,135	18.73	$77,448.55	2,959,308	4
2024-02-23	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	2,838	18.76	$53,240.88	46,245	4
2024-01-09	Frates, James M	Officer	Chief Financial Officer	Direct	Sale	2,716	16.33	$44,352.28	112,035	4
2024-01-09	Klee, Justin B.	Director,Officer	Co-Chief Executive Officer	Direct	Sale	5,841	16.33	$95,383.53	2,836,776	4
2024-01-09	Cohen, Joshua B	Director,Officer	Co-Chief Executive Officer	Direct	Sale	5,841	16.33	$95,383.53	2,900,470	4
2024-01-09	Yeramian, Patrick D	Officer	Chief Medical Officer	Direct	Sale	2,812	16.33	$45,919.96	205,605	4
2023-12-15	Firestone, Karen	Director	-	Direct	Purchase	4,000	14.97	$59,880.00	5,000	4
2023-08-15	Mazzariello, Gina	Officer	Chief Legal Officer	Direct	Sale	6,164	20.88	$128,704.32	49,083	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

102.68%

Inst. Shares: 113,531,472

Shares Outstanding: 110,563,360

2025-12-31

118.30%

Inst. Shares: 111,868,351

Shares Outstanding: 94,565,567

2025-09-30

115.61%

Inst. Shares: 107,901,945

Shares Outstanding: 93,332,930

2025-06-30

90.52%

Inst. Shares: 80,692,501

Shares Outstanding: 89,138,568

2025-03-31

85.31%

Inst. Shares: 73,109,510

Shares Outstanding: 85,697,108

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	113,531,472	110,563,360	102.68%
2025-12-31	111,868,351	94,565,567	118.30%
2025-09-30	107,901,945	93,332,930	115.61%
2025-06-30	80,692,501	89,138,568	90.52%
2025-03-31	73,109,510	85,697,108	85.31%
2024-12-31	48,840,659	68,142,158	71.67%
2024-09-30	41,144,282	68,091,446	60.43%
2024-06-30	41,951,346	68,024,929	61.67%
2024-03-31	47,450,257	67,854,356	69.93%
2023-12-31	58,298,144	67,234,465	86.71%
2023-09-30	57,645,967	67,414,669	85.51%
2023-06-30	51,171,885	67,233,617	76.11%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Amylyx Pharmaceuticals, Inc. (AMLX) — SEC Financial Statements & Analysis

Amylyx Pharmaceuticals, Inc. (AMLX) is a pharmaceutical preparations company, incorporated in DE. Amylyx Pharmaceuticals, Inc. trades on Nasdaq as: AMLX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Amylyx Pharmaceuticals, Inc. reported a -100.00% year-over-year revenue growth, a Gross Profit Margin of 89.49% (TTM), a Debt-to-Equity ratio of 0.11x, a Price-to-Sales (P/S) ratio of -1907.36x (TTM), a Price-to-Book (P/B) ratio of 8.35x (TTM), at a market cap of $2.00B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Gross Profit Margin TTM: 89.49%
Debt To Equity: 0.11x
P/S TTM: -1907.36x
P/B TTM: 8.35x
Market Cap: $2.00B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Amylyx Pharmaceuticals, Inc. in?

Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Pharmaceutical Preparations industry.

What is AMLX's market cap?

Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $2.00B as of 2026-06-30.

What exchange does AMLX trade on?

Amylyx Pharmaceuticals, Inc. (AMLX) trades on the Nasdaq.

Where is Amylyx Pharmaceuticals, Inc. incorporated?

Amylyx Pharmaceuticals, Inc. is incorporated in DE.